#033: May 27th, 2021 - Longevity Marketcap Telemetry

1. Announcements

2. Last Week in Longevity

3. Longevity Futures

4. Capital Raise Radar

5. Longevity Jobs

6. New Companies on Longevity List 

7. How to Start a Longevity Biotech Company

8. My Links

*Disclaimer: None of this should be taken as financial advice. It is for educational purposes only.

Mission: To grow a wave of passionate people building, funding, and championing technologies that extend healthy human lifespan. 

If you want to be part of this mission alongside me, please consider supporting through Patreon or Longevity List Merch.

📢 Announcements 

• forum.longevitybase.org - A “StackExchange / Quora” for aging biology / longevity biotech. In open beta right now. Feel free to sign up and try it out. Email me if you would like to become a moderator or if you have some suggestions.

• The Longevity Biotech Show is officially a podcast! Check us out on Spotify and also Apple Podcasts.

• Longevity Virtual Coworking. Every Friday. Drop in hours: 12PM - 5PM EDT. If you are working on longevity or thinking about getting into the longevity industry, please join me for an experimental virtual longevity coworking space using the Pluto.Video web app. (No sign-up required.) (Room Link)  

• The 1% Bet for Longevity-- a website initiative.39 people have now signed up for the 1% Bet for Longevity Pledge. My goal is to get to 50,000 people and at least 100 companies to pledge 1% of their resources towards funding longevity companies and research by the end of the year. 

• Humans For Longevity. A project featuring a collection of stories from people who care about longevity and their motivations.

📝 Last Week in Longevity

• Oisin Biotechnologies raises $5M seed round. Oisin Biotechnologies is a preclinical-stage gene therapy longevity company founded by Matt Scholz and Gary Hudson. This week the company announced the completion of a $5M oversubscribed seed round led by Althea Capital LLC. The company plans to use the capital to advance its preclinical studies, with results in chronic kidney disease coming later this year.
  
  Oisin’s lead program is a senolytic gene therapy for chronic kidney disease. In preclinical studies, the company’s therapy was able to reduce senescent cell burden in naturally aged mice and also extend lifespan by 20 percent. On The Longevity Biotech Show podcast two weeks ago, Matt Scholz stated that Oisin was planning to enter the clinic in 18 months. 

  Oisin’s technology uses a unique